Linlin Kuang

Dr. Linlin Kuang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YBYanhong Bie
Yanhong Bie
MBMeiying Bie
Meiying Bie
WLWang Liu
Wang Liu
STShufang Tao
Shufang Tao
HXHongyu Xing
Hongyu Xing
YSYi Song
Yi Song
Zinc Finger and BTB Domain-containing7A (ZBTB7A) is a member of the transcription factor family that regulates the expression of numerous genes involved in cell proliferation and differentiation. Ubiquitously expressed in colon, stomach, and other tissues, ZBTB7A performs diverse functions including hematopoiesis, metabolism, and oncogenesis. Here we showed that ZBTB7A knockout inhibited the growth of colon cancer cells and reduced CD95 protein expression by decreasing CD95 mRNA transcription. Overexpression of ZBTB7A could partially restore both CD95 expression and CD95-mediated downstream Caspase2 and JNK2 expression. Furthermore, treatment with ZBTB7A specific inhibitor Curcumin effectively induced colorectal cancer cell death while reducing CD95 expression. These data indicate that ZBTB7A promotes colon cancer cell growth and survival, suggesting its potential as a therapeutic target for colorectal cancer.

4 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
YYYannan Yin
Yannan Yin
JZJinkai Zang
Jinkai Zang
HSHuichun Shi
Huichun Shi
ZWZhuang Wang
Zhuang Wang
LKLinlin Kuang
Linlin Kuang
ZHZhong Huang
Zhong Huang
Background: It is still challenging to develop effective vaccines against tumorigenic human gammaherpesviruses such as Epstein–Barr virus (EBV). A major obstacle is the lack of a small animal model that reproduces the natural infection course of human gammaherpesviruses to allow for proper assessment of vaccine efficacy. Murine gammaherpesvirus 68 (MHV68) is a natural pathogen of wild rodents and laboratory mice and therefore can be used as a surrogate for human gammaherpesviruses to evaluate vaccination strategies. Methods: In this study, two mRNA vaccine candidates were generated, one encoding a fusion protein of the MHV68 gH with the gL (gHgL-mRNA) and the other expressing the MHV68 gB protein (gB-mRNA). The immunogenicity and protective efficacy of the mRNA vaccine candidates were evaluated in a mouse model of MHV68 infection. Results: The gHgL-mRNA but not the gB-mRNA candidate vaccine was able to induce neutralizing antibodies in mice, whereas both vaccines could elicit antigen-specific T-cell responses. Following MHV68 intranasal inoculation, complete blocking of the establishment of viral latency was observed in some mice immunized with individual gHgL-mRNA or gB-mRNA vaccines. Notably, co-immunization with the two mRNA vaccines appeared to be more effective than individual vaccines, achieving sterile immunity in 50% of the vaccinated mice. Conclusions: This study demonstrates that immunization with mRNA platform-based subunit vaccines is indeed capable of preventing MHV68 latent infection, thus validating a safe and efficacious vaccination strategy that may be applicable to human gammaherpesviruses.